Hawkins offers a durable municipal water-treatment moat and compelling PFAS growth, but leverage and multiple compression leave the five-year risk/reward modestly unfavorable.
Overview
Hawkins is a specialty chemical manufacturer and distributor serving more than 8,000 municipal and industrial sites through 66 facilities and over 2 million square feet of capacity. Its moat rests on localized just-in-time logistics, a fleet of more than 400 trucks, technical route personnel, integrated dosing equipment, and compliance expertise that create meaningful switching costs in municipal water treatment. **Water Treatment is the principal growth driver**, with fiscal 2026 sales up 22% to $543.3 million and segment gross margin holding at 27%, while Food and Health Sciences declined 1% amid pricing pressure. Fiscal 2026 sales reached a record $1.0837 billion, up 11.2%, but GAAP EPS fell to $3.91 from $4.03 as acquisition-related interest, amortization, fair-value adjustments, and LIFO charges weighed on earnings. The stock’s valuation remains demanding at approximately 34.8x trailing GAAP P/E and about 19x EV/EBITDA. Near-term catalysts include WaterSurplus accretion in fiscal 2027, deleveraging toward 1.0x Adjusted EBITDA, PFAS-related demand, and Food and Health Sciences stabilization; however, the five-year probability-weighted target of $130.01 is below the $136.26 reference price.